Gary K. Lee - Feb 11, 2022 Form 4 Insider Report for Lyell Immunopharma, Inc. (LYEL)

Role
Chief Scientific Officer
Signature
/s/ Heather Turner, as Attorney-in-Fact
Stock symbol
LYEL
Transactions as of
Feb 11, 2022
Transactions value $
$0
Form type
4
Date filed
2/14/2022, 07:59 PM
Previous filing
Feb 4, 2022
Next filing
Feb 28, 2023

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction LYEL Option (right to buy) Award $0 +800K $0.00 800K Feb 11, 2022 Common Stock 800K $6.04 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 1/4 of the option shares shall vest on January 31, 2023, with the remaining option shares to vest in equal monthly installments over the following thirty-six months.